Sugi Predict

Sugi Predict / Compounds / SCHEMBL446166

SCHEMBL446166

SCHEMBL446166

Fc1[c]cc2cc[nH]c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.52
▸ AHR P35869 7/20 0.50
▸ CMA1 P23946 1/20 0.41
▸ TYR P14679 1/20 0.41
▸ CYP2A6 P11509 2/20 0.37
▸ ENPP2 Q13822 2/20 0.37
▸ CSNK2A1 P68400 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TRPA1 O75762 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ ITGB2 P05107 1/20 0.37
▸ ICAM1 P05362 1/20 0.37
▸ ITGAL P20701 1/20 0.37
▸ CA4 P22748 1/20 0.37
▸ CA6 P23280 1/20 0.37
▸ ADK P55263 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843921 0.83 GPR84 (0.52) GPR84AHRCMA1TYRCYP2A6
SCHEMBL4126650 0.75 GPR84 (0.42) GPR84AHRCMA1TYRCYP2A6
SCHEMBL4465171 0.75 AHR (0.50) GPR84AHRCMA1TYRCYP2A6
SCHEMBL4459454 0.71 MEN1 (0.50) GPR84AHRCMA1TYRCYP2A6
SCHEMBL4468159 0.70 AHR (0.32) AHR
SCHEMBL19400087 0.69 PARP1 (0.44) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2530865 0.69 GPR84 (0.67) GPR84AHRCMA1TYRCYP2A6
SCHEMBL1393260 0.69 — —
SCHEMBL188052 0.69 GPR84 (1.00) GPR84AHRCMA1TYRCYP2A6
SCHEMBL29361924 0.67 AHR (1.00) GPR84AHRCMA1TYRCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 — — EP claimed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US claimed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 — — US claimed
US-20060148819-A1 Chemical compounds HENNEQUIN LAURENT F A 2006-07-06 — — US claimed
US-6887874-B2 Cinnoline compounds ASTRAZENECA AB (SE) 2005-05-03 — — US claimed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 — — US claimed
US-20030207878-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-11-06 — — US claimed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US claimed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 — — EP claimed
EP-1311500-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-21 — — EP claimed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 — — EP claimed
WO-2002016348-A1 ANTIANGIOGENIC BICYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO claimed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO claimed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO claimed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO claimed
US-20200109139-A1 PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2020-04-09 — — US disclosed
US-20180273531-A1 PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2018-09-27 — — US disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 GPR84 1216/4885AHR 2475/4885CMA1 905/4885
US-20180273531-A1 PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF TYMP, TYMS, DPYD GPR84 2963/4885AHR 1718/4885CMA1 2687/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 GPR84 780/4885AHR 2761/4885CMA1 997/4885
US-20060148819-A1 Chemical compounds VEGFA, NOS3, FLT4 GPR84 1305/4885AHR 529/4885CMA1 352/4885
US-20200109139-A1 PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF TYMP, TYMS, DPYD GPR84 2963/4885AHR 1718/4885CMA1 2687/4885
US-20030207878-A1 Chemical compounds CYP3A7, HTR3C, CNR1 GPR84 944/4885AHR 514/4885CMA1 220/4885
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 GPR84 1198/4885AHR 1927/4885CMA1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.